Soleno Therapeutics Inc Total Assets
Soleno Therapeutics Inc total assets. Based on the latest financial reports, Soleno Therapeutics Inc (SLNO) holds total assets worth $608.39 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Soleno Therapeutics Inc for the company's overall valuation and market capitalisation.
Total Assets of Soleno Therapeutics Inc (2012–2025)
Total assets of Soleno Therapeutics Inc from 2012 to 2025. This chart illustrates how Soleno Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Soleno Therapeutics Inc stock quote for real-time trading data and today's change.
Soleno Therapeutics Inc - Asset Composition Analysis
Soleno Therapeutics Inc Total Assets Breakdown (December 2025)
Soleno Therapeutics Inc total assets breakdown as of December 2025. Soleno Therapeutics Inc's total assets of $608.39 Million consist of 63.1% current assets and 36.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.4% |
| Accounts Receivable | $28.21 Million | 5.0% |
| Inventory | $15.02 Million | 2.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.86 Million | 0.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Soleno Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Soleno Therapeutics Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Soleno Therapeutics Inc's current assets represent 63.1% of total assets in 2025, a decrease from 95.0% in 2012.
- Cash Position: Cash and equivalents constituted 12.4% of total assets in 2025, down from 85.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 5.0% of total assets.
Soleno Therapeutics Inc Competitors by Total Assets
Key competitors of Soleno Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Soleno Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.62 | 19.64 | 4.13 |
| Quick Ratio | 5.32 | 19.64 | 4.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $268.33 Million | $293.18 Million | $26.18 Million |
Soleno Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Soleno Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.13 |
| Latest Market Cap to Assets Ratio | 4.89 |
| Asset Growth Rate (YoY) | 70.4% |
| Total Assets | $563.83 Million |
| Market Capitalization | $2.76 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Soleno Therapeutics Inc's assets at a significant premium (4.89x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Soleno Therapeutics Inc's assets grew by 70.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Soleno Therapeutics Inc (2012–2025)
The table below shows the annual total assets of Soleno Therapeutics Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $563.83 Million | +70.36% |
| 2024-12-31 | $330.97 Million | +83.17% |
| 2023-12-31 | $180.69 Million | +581.93% |
| 2022-12-31 | $26.50 Million | -25.47% |
| 2021-12-31 | $35.55 Million | -45.29% |
| 2020-12-31 | $64.98 Million | +70.23% |
| 2019-12-31 | $38.17 Million | -11.54% |
| 2018-12-31 | $43.15 Million | +10.58% |
| 2017-12-31 | $39.02 Million | +601.22% |
| 2016-12-31 | $5.56 Million | -32.15% |
| 2015-12-31 | $8.20 Million | -2.32% |
| 2014-12-31 | $8.40 Million | +429.15% |
| 2013-12-31 | $1.59 Million | -36.89% |
| 2012-12-31 | $2.51 Million | -- |
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more